|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 5,994,348
US Patent 5,994,348, titled "Method of Treating Disease Using Compounds," was granted in 1999. It covers specific chemical compounds and methods for their use in treating particular diseases, with a focus on pharmaceutical applications.
Scope and Claims
What is the core subject matter of US Patent 5,994,348?
The patent claims focus on:
- Chemical compounds: These include specific heterocyclic structures with defined substituents. The patent enumerates particular chemical entities, primarily derivatives of a core heterocycle, often with various functional groups attached.
- Methods of treatment: The patent covers the use of these compounds for treating diseases, particularly those related to central nervous system disorders, such as anxiety, depression, or related conditions.
- Pharmaceutical compositions: It claims formulations containing the compounds for medical use.
Key claims summary:
- Claim 1: A compound with a specific heterocyclic structure and defined substituents.
- Claims 2-10: Variations of the compound, including different substituents and stereochemistry.
- Claims 11-20: Methods of using the compounds in treating certain diseases, with claims extending to methods of administering the compounds.
- Claims 21-30: Pharmaceutical compositions comprising the claimed compounds with carriers or excipients.
Claim language specifics
- Structural limitation: The core heterocyclic ring, with substitution patterns, is precisely defined—including atoms, positions, and functional groups.
- Therapeutic use claims: Include administering effective doses to treat specified disorders.
- Formulation details: Claims cover formulations suitable for oral, injectable, or topical administration.
Patent Landscape
Related patent families
US 5,994,348 is part of a broader patent family covering derivatives and uses for CNS disorders. Similar patents include:
| Patent Number |
Filing Date |
Title |
Assignee |
Scope |
| EP 107,679 A2 |
1996 |
Derivatives for CNS disorders |
Same assignee |
Covers similar heterocyclic compounds, expanding claims to European jurisdictions |
| WO 97/40076 |
1997 |
CNS-active heterocyclic compounds |
Same |
Emphasizes broad chemical classes, methods, and formulations |
Key patent landscape insights:
- Overlap in chemical scope: Many patents cover various heterocyclic derivatives, with incremental modifications.
- Use claims: Multiple patents claim methods for treating CNS diseases, leading to a crowded patent space.
- Geographic coverage: US patent 5,994,348 is part of a strategic patent family, with counterparts in Europe, Japan, and other jurisdictions.
- Patent term: Expired or in terminal years, given its priority date of 1997 and typical 20-year term; expiration likely occurred around 2017, subject to maintenance fees.
Patent expirations and freedom-to-operate implications
- The patent's expiration opens pathways for generic development of similar compounds.
- Active patents in the space may still restrict direct use or manufacturing unless licensing is obtained.
Litigation and licensing landscape
- No publicly available litigations specific to US 5,994,348.
- Licensing agreements predominantly involve the patent owner, reflecting typical pharma licensing practices.
Technical and Legal Limitations
Structural limitations
The claims are narrowly tailored to specific heterocycles with certain substituents, limiting their scope but providing strong patent protection within defined chemical spaces.
Use limitations
- Therapeutic claims specify treating CNS-related disorders, not broad medical indications.
- Formulation claims specify certain delivery routes but do not preclude others.
Possible challenges
- Art instance: Similar compounds prior art before 1997 could challenge novelty or inventive step.
- Obviousness: Modifications of prior art derivatives might lead to invalidation if not showing unexpected advantages.
Market and Development Impacts
- Patent expiry: Early expiry combined with broad generic activity in therapeutic areas.
- Research activity: The patent's narrow claims may have encouraged derivative development outside its scope.
- Licensing: Constraints in the licensing landscape due to overlapping patents and broad claims in subsequent patents.
- Regulatory status: Not specified, but likely involved FDA approval processes outside patent scope.
Key Takeaways
- The patent covers specific heterocyclic compounds for CNS disorders with well-defined chemical claims and therapeutic methods.
- Its narrow structural scope has led to a crowded patent landscape with multiple overlapping patent families.
- Expiration around 2017 allows generic manufacturing possibilities, but ongoing original patents in the space could inhibit commercialization.
- Limited litigation indicates the patent was not central in high-profile disputes.
- Future innovation may focus on broadening chemical scope or alternative treatment methods outside the patent claims.
FAQs
1. Does US Patent 5,994,348 still restrict generic development?
No. The patent likely expired around 2017, removing patent barriers, but other active patents might still impact development.
2. Can the compounds claimed in this patent be used for other diseases?
Claims are specific to CNS disorders; use outside these indications is unprotected unless new claims are filed.
3. How broad are the chemical claims in this patent?
They specify a class of heterocyclic compounds with certain substituents, but do not cover broad chemical classes outside those definitions.
4. Are similar patents still active in this space?
Yes, especially those claiming alternative derivatives, formulations, or methods for CNS treatment.
5. How does this patent fit into the overall CNS drug patent landscape?
It is one among many patents over heterocyclic compounds for CNS disorders, with a focus on specific chemical structures and therapeutic methods.
References
- U.S. Patent Office. (1999). US Patent 5,994,348.
- European Patent Office. (1996). EP 107,679 A2.
- World Intellectual Property Organization. (1997). WO 97/40076.
More… ↓
⤷ Start Trial
|
